Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level.
BACKGROUND
Transgenic cardiac beta(2)-adrenergic receptor (AR) overexpression has resulted in enhanced signaling and cardiac function in mice, whereas relatively low levels of transgenically expressed G(alphas) or beta(1)AR have resulted in phenotypes of ventricular failure. Potential relationships between the levels of betaAR overexpression and biochemical, molecular, and physiological consequences have not been reported.


RESULTS
We generated transgenic mice expressing beta(2)AR at 3690, 7120, 9670, and 23 300 fmol/mg in the heart, representing 60, 100, 150, and 350 times background betaAR expression. All lines showed enhanced basal adenylyl cyclase activation but a decrease in forskolin- and NaF-stimulated adenylyl cyclase activities. Mice of the highest-expressing line developed a rapidly progressive fibrotic dilated cardiomyopathy and died of heart failure at 25+/-1 weeks of age. The 60-fold line exhibited enhanced basal cardiac function without increased mortality when followed for 1 year, whereas 100-fold overexpressors developed a fibrotic cardiomyopathy and heart failure, with death occurring at 41+/-1 weeks of age. Adenylyl cyclase activation did not correlate with early or delayed decompensation. Propranolol administration reduced baseline +dP/dt(max) to nontransgenic levels in all beta(2)AR transgenics except the 350-fold overexpressors, indicating that spontaneous activation of beta(2)AR was present at this level of expression.


CONCLUSIONS
These data demonstrate that the heart tolerates enhanced contractile function via 60-fold beta(2)AR overexpression without detriment for a period of >/=1 year and that higher levels of expression result in either aggressive or delayed cardiomyopathy. The consequences for enhanced betaAR function in the heart appear to be highly dependent on which signaling elements are increased and to what extent.
Liggett
S B
SB
Department of Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio 45267-0590, USA.
Tepe
N M
NM
Lorenz
J N
JN
Canning
A M
AM
Jantz
T D
TD
Mitarai
S
S
Yatani
A
A
Dorn
G W
GW
D000818:Animals; D015220:Calcium Channels / Q000378:metabolism / Q000502:physiology; D002303:Cardiac Output, Low / Q000209:etiology / Q000401:mortality; D009202:Cardiomyopathies / Q000209:etiology / Q000473:pathology; D002311:Cardiomyopathy, Dilated / Q000000981:diagnostic imaging / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D004452:Echocardiography; D004553:Electric Conductivity; D005355:Fibrosis; D006439:Hemodynamics; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic / Q000235:genetics; D009200:Myocardial Contraction / Q000502:physiology; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D009994:Osmolar Concentration; D011446:Prospective Studies; D011943:Receptors, Adrenergic, beta / Q000378:metabolism*; D013997:Time Factors
D015220:Calcium Channels; D011943:Receptors, Adrenergic, beta